Loading
A phase 2 trial of Acasunlimab, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Genmab, stopped early.
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer is a phase 2 interventional study registered as NCT05117242 by Genmab, with 125 participants enrolled, started 2021-10-27 and reached its primary completion in 2024-12-02. Interventions recorded: Acasunlimab, Pembrolizumab. Conditions listed: Non Small Cell Lung Cancer Metastatic. No results are recorded here; the registry entry is the source.
Shares Acasunlimab, Genmab, Non-small-cell lung cancer.
Shares Genmab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Genmab, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Genmab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Genmab, Pembrolizumab, Non-small-cell lung cancer.
Shares Genmab, Pembrolizumab.
Shares Acasunlimab, Non-small-cell lung cancer.
Shares Genmab, Pembrolizumab.